BC Innovations | Jul 31, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD); neurology Calpain; calpastatin Mouse studies suggest inhibiting calpain could help treat AD and other neurodegenerative tauopathies. In a transgenic mouse tauopathy model,...
BC Innovations | Jan 9, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve injury Calpastatin; calpain In vitro and mouse studies suggest calpastatin, an inhibitor of the proteinase calpain, could help treat nerve injury. In cultured mouse...
BC Innovations | Dec 4, 2008
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Calpastatin (CAST) Studies in cell culture and in mice suggest that upregulating CAST in the brain could be...
BC Innovations | Apr 17, 2008
Targets & Mechanisms

Ramping Up Autophagy

The most common therapeutic approach to treat Huntington's disease and Parkinson's disease is to reduce the amount of the misfolding-prone proteins huntingtin and a-synuclein, respectively, before disease sets in. A study published in Nature Chemical...
BC Week In Review | Jun 10, 1996
Company News

Progen Biotechnik GmbH, University Hospital sales and marketing update

Progen began selling a peptide ELISA test developed in conjunction with University Hospital for clinical research in vascular medicine. The test detects auto-antibodies specific to the C-terminal 27 amino acids of calpastatin, an inhibitor of...
Items per page:
1 - 5 of 5